Publications
Multiscale adaptive marginal analysis of longitudinal neuroimaging data with time-varying covariates." Biometrics 68, no. 4 (2012): 1083-92.
"Gene selection using iterative feature elimination random forests for survival outcomes." IEEE/ACM Trans Comput Biol Bioinform 9, no. 5 (2012): 1422-31.
"Joint modeling of survival time and longitudinal outcomes with flexible random effects." Lifetime Data Anal 24, no. 1 (2018): 126-152.
"Set-valued dynamic treatment regimes for competing outcomes." Biometrics 70, no. 1 (2014): 53-61.
"Accelerated failure time model for data from outcome-dependent sampling." Lifetime Data Anal 27, no. 1 (2021): 15-37.
"Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
"Semiparametric regression analysis of interval-censored data with informative dropout." Biometrics 74, no. 4 (2018): 1213-1222.
"Detection of gene-gene interactions using multistage sparse and low-rank regression." Biometrics 72, no. 1 (2016): 85-94.
"Incorporating higher-order representative features improves prediction in network-based cancer prognosis analysis." BMC Med Genomics 4 (2011): 5.
"Allele-specific copy-number discovery from whole-genome and whole-exome sequencing." Nucleic Acids Res 43, no. 14 (2015): e90.
"Analysis of gene-gene interactions using gene-trait similarity regression." Hum Hered 78, no. 1 (2014): 17-26.
"fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies." BMC Bioinformatics 20, no. 1 (2019): 333.
"Efficient estimation for accelerated failure time model under case-cohort and nested case-control sampling." Biometrics 73, no. 1 (2017): 114-123.
"Probability-enhanced sufficient dimension reduction for binary classification." Biometrics 70, no. 3 (2014): 546-55.
"Radiomics analysis using stability selection supervised component analysis for right-censored survival data." Comput Biol Med 124 (2020): 103959.
"A moment-adjusted imputation method for measurement error models." Biometrics 67, no. 4 (2011): 1461-70.
"Multiscale adaptive generalized estimating equations for longitudinal neuroimaging data." Neuroimage 72 (2013): 91-105.
"Subgroup detection and sample size calculation with proportional hazards regression for survival data." Stat Med 36, no. 29 (2017): 4646-4659.
"TEAM: efficient two-locus epistasis tests in human genome-wide association study." Bioinformatics 26, no. 12 (2010): i217-27.
"Maximum likelihood estimation in generalized linear models with multiple covariates subject to detection limits." Stat Med 30, no. 20 (2011): 2551-61.
"Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data." Biometrics 74, no. 4 (2018): 1180-1192.
"Fitting Nonlinear Ordinary Differential Equation Models with Random Effects and Unknown Initial Conditions Using the Stochastic Approximation Expectation-Maximization (SAEM) Algorithm." Psychometrika 81, no. 1 (2016): 102-34.
"Global copy number profiling of cancer genomes." Bioinformatics 32, no. 6 (2016): 926-8.
"A general framework for integrative analysis of incomplete multiomics data." Genet Epidemiol 44, no. 7 (2020): 646-664.
"CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method." Comput Methods Programs Biomed 176 (2019): 211-223.
"Assessing gene-environment interactions for common and rare variants with binary traits using gene-trait similarity regression." Genetics 199, no. 3 (2015): 695-710.
"Reexamining Dis/Similarity-Based Tests for Rare-Variant Association with Case-Control Samples." Genetics 209, no. 1 (2018): 105-113.
"Rapid and robust resampling-based multiple-testing correction with application in a genome-wide expression quantitative trait loci study." Genetics 190, no. 4 (2012): 1511-20.
"Efficient semiparametric estimation of short-term and long-term hazard ratios with right-censored data." Biometrics 69, no. 4 (2013): 840-9.
"Using Structural Equation Modeling to Assess the Links between Tobacco Smoke Exposure, Volatile Organic Compounds, and Respiratory Function for Adolescents Aged 6 to 18 in the United States." Int J Environ Res Public Health 14, no. 10 (2017).
"Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI." Neuroimage 56, no. 3 (2011): 890-906.
"Diffusion tensor imaging-based characterization of brain neurodevelopment in primates." Cereb Cortex 23, no. 1 (2013): 36-48.
"Multisensory Logic of Infant-Directed Aggression by Males." Cell 175, no. 7 (2018): 1827-1841.e17.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Clinical prognostic model for older patients with advanced non-small cell lung cancer." J Geriatr Oncol 10, no. 4 (2019): 555-559.
"Robust test method for time-course microarray experiments." BMC Bioinformatics 11 (2010): 391.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Assessing the causal effect of organ transplantation on the distribution of residual lifetime." Biometrics 69, no. 4 (2013): 820-9.
"SMAC: Spatial multi-category angle-based classifier for high-dimensional neuroimaging data." Neuroimage 175 (2018): 230-245.
"Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer." Cancer 121, no. 6 (2015): 836-43.
"Genetic variation determines VEGF-A plasma levels in cancer patients." Sci Rep 8, no. 1 (2018): 16332.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Latent class model characterization of neighborhood socioeconomic status." Cancer Causes Control 27, no. 3 (2016): 445-52.
"Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198.
"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data." J Alzheimers Dis 46, no. 3 (2015): 695-702.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Latent class model characterization of neighborhood socioeconomic status." Cancer Causes Control 27, no. 3 (2016): 445-52.
"Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198.
"Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012." J Clin Oncol 34, no. 33 (2016): 3992-3999.
"Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials." Stat Med 33, no. 27 (2014): 4715-33.
"Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI." Neuroimage 56, no. 3 (2011): 890-906.
"Bayesian probability of success for clinical trials using historical data." Stat Med 34, no. 2 (2015): 249-64.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
"Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy." Clin Pharmacol Ther 108, no. 3 (2020): 625-634.
"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer." J Thorac Oncol 10, no. 7 (2015): 1099-106.
"Precision Medicine Approach to Develop and Internally Validate Optimal Exercise and Weight-Loss Treatments for Overweight and Obese Adults With Knee Osteoarthritis: Data From a Single-Center Randomized Trial." Arthritis Care Res (Hoboken) 73, no. 5 (2021): 693-701.
"Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data." J Alzheimers Dis 46, no. 3 (2015): 695-702.
"Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer." Lung Cancer 141 (2020): 14-20.
"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
"Genetic association analysis under complex survey sampling: the Hispanic Community Health Study/Study of Latinos." Am J Hum Genet 95, no. 6 (2014): 675-88.
"Clinical prognostic model for older patients with advanced non-small cell lung cancer." J Geriatr Oncol 10, no. 4 (2019): 555-559.
"Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION)." Am Heart J 165, no. 2 (2013): 193-9.
"Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups." Lung Cancer 90, no. 2 (2015): 281-7.
"On model selections for repeated measurement data in clinical studies." Stat Med 34, no. 10 (2015): 1621-33.
"Robust test method for time-course microarray experiments." BMC Bioinformatics 11 (2010): 391.
"Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies." J Clin Oncol 35, no. 25 (2017): 2885-2892.
"Ten-year experience with extended criteria cardiac transplantation." Circ Heart Fail 6, no. 6 (2013): 1230-8.
"Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." J Clin Oncol 34, no. 9 (2016): 945-52.
"Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer." Am J Mens Health 10, no. 5 (2016): 399-407.
"Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia." Ann Oncol 30, no. 4 (2019): 542-550.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"Assessing the causal effect of organ transplantation on the distribution of residual lifetime." Biometrics 69, no. 4 (2013): 820-9.
"A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101." Clin Cancer Res 18, no. 18 (2012): 5099-109.
"SMAC: Spatial multi-category angle-based classifier for high-dimensional neuroimaging data." Neuroimage 175 (2018): 230-245.
"Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer." Cancer 121, no. 6 (2015): 836-43.
"Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome." Eur Heart J 37, no. 4 (2016): 412-22.
"Genetic variation determines VEGF-A plasma levels in cancer patients." Sci Rep 8, no. 1 (2018): 16332.
"Factor selection and structural identification in the interaction ANOVA model." Biometrics 69, no. 1 (2013): 70-9.
"Inference on phenotype-specific effects of genes using multivariate kernel machine regression." Genet Epidemiol 42, no. 1 (2018): 64-79.
"Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012." J Clin Oncol 34, no. 33 (2016): 3992-3999.
"A varying-coefficient generalized odds rate model with time-varying exposure: An application to fitness and cardiovascular disease mortality." Biometrics 75, no. 3 (2019): 853-863.
"Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies." J Clin Oncol 35, no. 25 (2017): 2885-2892.
"Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia." Ann Oncol 30, no. 4 (2019): 542-550.
"Age and African-American race impact the validity and reliability of the asthma control test in persistent asthmatics." Respir Res 19, no. 1 (2018): 152.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Assessing the causal effect of organ transplantation on the distribution of residual lifetime." Biometrics 69, no. 4 (2013): 820-9.
"Bayesian estimation of semiparametric nonlinear dynamic factor analysis models using the Dirichlet process prior." Br J Math Stat Psychol 64, no. Pt 1 (2011): 69-106.
"Bayesian lasso for semiparametric structural equation models." Biometrics 68, no. 2 (2012): 567-77.
"Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
"A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101." Clin Cancer Res 18, no. 18 (2012): 5099-109.
"Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs." Stat Med 32, no. 23 (2013): 3972-90.
"Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer." J Natl Cancer Inst 104, no. 3 (2012): 211-27.
"Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
"Genetic variation determines VEGF-A plasma levels in cancer patients." Sci Rep 8, no. 1 (2018): 16332.
"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res 19, no. 1 (2017): 18.
"Latent class model characterization of neighborhood socioeconomic status." Cancer Causes Control 27, no. 3 (2016): 445-52.
"Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198.
"Estimating effect of environmental contaminants on women's subfecundity for the MoBa study data with an outcome-dependent sampling scheme." Biostatistics 15, no. 4 (2014): 636-50.
"